Accuray Incorporated (ARAY)
NasdaqGS
Price as at 30 Sept 2026, 16:04 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Accuray Incorporated trades at $0.27. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Accuray Incorporated
Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, a tailored helical solution, which integrates radiation treatment planning, delivery, imaging, and data management; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
8 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$701.0K · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$532.4K · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$409.7K · 0.0% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$167.4K · 0.0% of book
- Paul Tudor Jones, TUDOR INVESTMENT CORP ET AL$101.1K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own ARAY?
8 of the institutions we track reported a position in ARAY in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its ARAY data?
Fundamentals for ARAY come from company filings and exchange data, as listed on NasdaqGS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:04 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for ARAY, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.